Literature DB >> 12114214

Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.

Desi J Penington1, Ianthe Bryant, David J Riese.   

Abstract

ErbB4 is a member of the epidermal growth factor receptor(EGFR) family of tyrosine kinases, which includes EGFR/ErbB1, ErbB2/HER2/Neu, and ErbB3/HER3. These receptors play important roles both in normal development and in neoplasia. For example, deregulated signaling by ErbB1 and ErbB2 is observed in many human malignancies. In contrast, the roles that ErbB4 plays in tumorigenesis and normal biological processes have not been clearly defined. To identify the biological responses that are coupled to ErbB4, we have constructed three constitutively active ErbB4 mutants. Unlike a constitutively active ErbB2 mutant, the ErbB4 mutants are not coupled to increased cell proliferation, loss of contact inhibition, or anchorage independence in a rodent fibroblast cell line. This suggests that ErbB2 and ErbB4 may play distinct roles in tumorigenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12114214

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  15 in total

1.  Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.

Authors:  Caren V Lund; Mikhail Popkov; Laurent Magnenat; Carlos F Barbas
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

2.  Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

Authors:  Richard M Gallo; Ianthe Bryant; Rachael Fry; Eric E Williams; David J Riese
Journal:  Biochem Biophys Res Commun       Date:  2006-08-18       Impact factor: 3.575

3.  The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Authors:  Richard M Gallo; David J Riese
Journal:  Growth Factors       Date:  2007-10       Impact factor: 2.511

Review 4.  EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling.

Authors:  Kristy J Wilson; Christopher Mill; Sydney Lambert; Jennifer Buchman; Timothy R Wilson; Victor Hernandez-Gordillo; Richard M Gallo; Laura M C Ades; Jeffrey Settleman; David J Riese
Journal:  Growth Factors       Date:  2012-01-20       Impact factor: 2.511

5.  The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.

Authors:  Kristy J Wilson; Christopher P Mill; Richard M Gallo; Elizabeth M Cameron; Henry VanBrocklin; Jeffrey Settleman; David J Riese
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

6.  Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.

Authors:  Jorma A Määttä; Maria Sundvall; Teemu T Junttila; Liisa Peri; V Jukka O Laine; Jorma Isola; Mikala Egeblad; Klaus Elenius
Journal:  Mol Biol Cell       Date:  2005-10-26       Impact factor: 4.138

7.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

8.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

Authors:  Christopher P Mill; Kathleen L Gettinger; David J Riese
Journal:  Exp Cell Res       Date:  2010-11-24       Impact factor: 3.905

9.  The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.

Authors:  Shu-Mang Feng; Rebecca S Muraoka-Cook; Debra Hunter; Melissa A Sandahl; Laura S Caskey; Keiji Miyazawa; Azeddine Atfi; H Shelton Earp
Journal:  Mol Cell Biol       Date:  2008-12-01       Impact factor: 4.272

10.  Gene copy numbers of HER family in breast cancer.

Authors:  Anna Zaczek; Marzena Wełnicka-Jaśkiewicz; Krzysztof Piotr Bielawski; Janusz Jaśkiewicz; Andrzej Badzio; Włodzimierz Olszewski; Piotr Rhone; Jacek Jassem
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.